Emory Alzheimer's Disease Research Center

埃默里阿尔茨海默病研究中心

• 批准号: 10408026
• 负责人: Thomas Spurgeon Wingo
• 金额: $ 42.18万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10408026
• 关键词: Alzheimer' s Disease; Alzheimer' s disease risk; Alzheimer' s disease therapy; Alzheimer’s disease biomarker; Amyloid beta-42; Area; Biological Assay; Biological Markers; Brain; Brain imaging; Chronic Disease; Clinical; Clinical Trials; Collection; Communities; Complement; Consult; DNA Resequencing; Data; Data Analyses; Data Mart; Data Set; Databases; Dementia; Diagnosis; Disease; Elements; Eligibility Determination; Ensure; Environment; Etiology; Foundations; Funding; Genes; Genetic; Genotype; Goals; Human; Individual; Inherited; Intervention; Learning; Magnetic Resonance Imaging; Methods; Participant; Pathology; Population; Positron-Emission Tomography; Procedures; Process; Proteomics; Protocols documentation; Quality Control; Race; Research; Research Activity; Research Personnel; Research Support; Sampling; Services; Standardization; System; Talents; Testing; Work; base; biomarker discovery; brain magnetic resonance imaging; candidate marker; cohort; complex data; genetic analysis; genetic information; genetic profiling; genomic data; genotypic sex; innovation; mild cognitive impairment; mutation carrier; neuroimaging; neuropathology; novel marker; prognostic; recruit; repository; response; risk variant; serial imaging; tau Proteins; tau-1; tool; whole genome

SUMMARY/ABSTRACT: BIOMARKER CORE Alzheimer’s disease (AD) is a chronic disease that progresses through a lengthy asymptomatic period before entering a period of mild cognitive impairment (MCI) and dementia. Using current biomarker tools, we can determine with a fair degree of confidence whether or not AD-related pathology is present in a living individual. However, there remain major limitations in the capabilities of AD biomarkers, and there is a critical need for new biomarkers to overcome remaining barriers. The proposed Biomarker Core will support research activities in the Emory ADRC by pursuing three Specific Aims: 1) Perform and analyze standardized genetic profiling and explore promising candidates; 2) Perform and analyze standardized CSF AD biomarker assays and explore promising candidates; 3) Perform and analyze standard brain imaging and evaluate promising additional sequences. The proposed Biomarker Core will provide a number of important enhancements to the research environment. Longitudinal collection of common datasets, including clinical information, CSF AD biomarkers, core genetic information, and standard brain MRI sequences, will provide foundations upon which new AD biomarkers can be tested, evaluated, and confirmed. Exploratory research in each of these areas should provide significant advances in CSF proteomics, new MR sequences, and genomic data. Lastly, the current proposal engages a group of talented investigators who will bring their expertise to the ADRC and the larger research community. Each of these elements advance the overall goals of the ADRC and will provide a wealth of data for new trainees.

总结/摘要：生物标志物核心 阿尔茨海默病（AD）是一种慢性疾病，通过漫长的无症状期进展 在进入轻度认知障碍（MCI）和痴呆期之前。使用当前生物标志物 工具，我们可以确定是否有相当程度的信心，是否存在AD相关的病理 在一个活生生的人身上。然而，AD生物标志物的能力仍然存在重大限制， 迫切需要新的生物标志物来克服剩余的障碍。拟议的生物标志物 核心将通过追求三个具体目标来支持埃默里ADRC的研究活动：1）执行 并分析标准化的基因图谱，探索有前途的候选人; 2）执行和分析 标准化CSF AD生物标志物测定并探索有希望的候选物; 3）进行并分析 标准脑成像并评估有希望的附加序列。生物标志物核心 将为研究环境提供一些重要的增强。纵向收集 常见数据集，包括临床信息、CSF AD生物标志物、核心遗传信息和 标准的脑MRI序列，将为新的AD生物标志物的测试提供基础， 评估和确认。在这些领域的探索性研究应该提供重要的 CSF蛋白质组学的进展，新的MR序列和基因组数据。最后，目前的建议 聘请了一批有才华的调查人员，他们将把自己的专业知识带到ADRC和更大的 研究社区。这些要素中的每一个都推进了ADRC的总体目标，并将提供一个 为新学员提供丰富的数据。